J. LAMARCK
BIOTECH FUND

SELECTRA SICAV part of TMF GROUP

# J. Lamarck Biotech - Class C

**September 2026**

LU1053929581

selectra.tmf-group.com

UCITS IV SICAV

www.lamarcksicav.eu


## Investment strategy

The main objective of this sub-fund is to profit from increasing share prices in the biotechnology sector.
The focus is on mature top tier pharmaceutical biotech companies and companies with interesting pipeline of products in development in a single or numerous markets, like Nasdaq or NYSE. The followed investment policy will enable the Sub-Fund to increase overall return relative to the Nasdaq Biotech Index by active stock selection of companies, offering the most promising technology platform.

## Cumulative fund performance

| | Fund |
|---|---|
| YTD | 5.10% |
| 1 month | -6.79% |
| 3 months | -8.76% |
| 6 months | 2.85% |
| 1 year | 8.94% |
| From Inception * | 76.40% |


## Fund performance




## Drawdown analysis

| Depth | Length | Recovery | Peak | Valley |
|---|---|---|---|---|
| -40.84% | 26 | - | Aug-21 | Oct-23 |
| -41.94% | 32 | - | Aug-21 | Apr-24 |
| -48.19% | 43 | - | Aug-21 | Mar-25 |

## Industry sector allocation




## Top 5 holdings

| Asset | Market Value (EUR) | % AUM |
|---|---|---|
| Denali Therapeutics Inc Reg | 5,641,078 | 8.1 |
| Ionis Pharmaceuticals Inc | 4,716,965 | 6.8 |
| Intellia Therapeutics Inc | 3,928,339 | 5.6 |
| CRISPR Therapeutics AG Reg | 3,457,804 | 5.0 |
| Biogen Inc | 3,380,544 | 4.8 |

## Fund data

| | |
|---|---|
| **NAV class C (30.09.2026)** | EUR 385.24 |
| **AUM** | EUR 66.95 Mio |
| **Launch date** | June 20th, 2014 |
| **Domiciliation** | 2, rue d'Alsace, L-1122 Luxembourg |
| **R.C.S.** | Luxembourg, B136880 |
| **Investment Manager** | J. Lamarck Asset Management S.A. |
| **Auditor** | Deloitte Audit S.à r.l. |
| **Depositary Bank** | Quintet Private Bank (Europe) S.A. |
| **Contact** | TMF Fund Management S.A.<br>46A, Avenue John F. Kennedy<br>L-1855 Luxembourg<br>Tel: +352 42 71 71 1<br>info.fundmanagement@tmf-group.com |

## Investment terms

| | Class A | Class B | Class C | Class D |
|---|---|---|---|---|
| **Advisory Fee** | up to 1.30% p.a | up to 2.50% p.a | up to 2.50% p.a | up to 2.50% p.a |
| **Minimum amount invested** | EUR 1,000,000 | EUR 5,000 | EUR 5,000 | 1 share |
| **Performance fee** | 20% p.a with HWM** | 20% p.a with HWM** | 20% p.a with HWM** | 20% p.a with HWM** |
| **Bloomberg ticker** | SELJLBT LX | SELJLBB LX | SELJBC LX | SELJLB IM |
| **ISIN** | LU0574993464 | LU0574994512 | LU1053929581 | LU1246176264 |

* Inception Date: June 20th, 2014

** High Water Mark

**For more details regarding the investment in this Fund, including potential risks, please refer to the current Full or Simplified Prospectus (the "Prospectus") available at SIS's offices.**
This Fund is a sub-fund of the Luxembourg-registered Selectra Investments SICAV ("SIS").This document has been prepared solely for information purposes and shall not be considered as an advice or solicitation to invest in SIS. Shares in SIS will only be issued and distributed on the basis of the Prospectus. The strategy employed may result in the Net Asset Value of the Fund exhibiting a high level of volatility and SIS is only suitable for investors in a position to take such risks. The value of investments may go down as well up and you may not get back your original investment. Changes in rate of exchange between currencies may cause the value of investments to decrease or increase. No liability whatsoever is accepted by SIS for any loss howsoever arising from any use of this report or its contents.